Key result
Continuation of antiplatelet therapy during mandibular third molar extraction resulted in minimal oozing at 24 hours (7.5%) compared to discontinuation (5.0%), indicating minor surgical procedures can be performed without stopping therapy.
Why the study?
Antiplatelet therapy is used to treat thromboembolic disorders but may cause hemorrhages during minor surgical procedures, necessitating assessment of its effects.
Does continuation of antiplatelet therapy increase bleeding in patients undergoing mandibular third molar extraction?
RCT (n=80)
Randomly divided
Does continuation of antiplatelet therapy increase bleeding in patients undergoing mandibular third molar extraction?
Absolute Event Rate: 7.5% vs 5%
p-value: p=0.04
Continuing antiplatelet therapy (aspirin or clopidogrel) during mandibular third molar extraction does not result in clinically significant bleeding compared to discontinuing therapy 5 days prior.
Background: Antiplatelet therapy is to treat thromboembolic disorders, but it causes hemorrhages. Aspirin is the drug in regular practice. The present study was conducted to assess the effect of anti- platelet therapy on minor surgical procedures. Materials & Methods: 80 patients selected for mandibular third molar extraction of both genders were randomly divided into 2 groups of 40 each. In Group I, patients on antiplatelets drugs (75 mg of aspirin/ 75 mg clopidogrel) were enrolled and in group II, patients who discontinued the drug before 5 days of extraction of mandibular third molar were enrolled. Bleeding was observed after 1 and 24 hours. Results: Group I had 24 males and 16 females and group II had 14 males and 26 females. The mean bleeding time in group I was 75.21 seconds and in group II was 75.14 seconds. The mean duration of surgery in group I was 54.2 months and in group II was 52.1 months. After 1 hour, no bleeding was seen in 38 in group I and 39 in group II and ooze in 2 in group I and 1 in group II.
No takes yet. Share an insight, caveat, or question.
Saify et al. (2022) conducted an RCT in Patients on antiplatelet therapy requiring mandibular third molar extraction (n=80). Continuation of antiplatelet therapy (aspirin or clopidogrel) vs. Discontinuation of antiplatelet therapy 5 days before extraction was evaluated on Post-operative bleeding (ooze) at 24 hours (p=0.04). Continuation of antiplatelet therapy during mandibular third molar extraction resulted in minimal oozing at 24 hours (7.5%) compared to discontinuation (5.0%), indicating minor surgical procedures can be performed without stopping therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: